Nabriva Therapeutics Inc. (NBRV) stock gains during pre-market trading. Here’s what you should know?

AMD Stock
AMD Stock

Nabriva Therapeutics Inc. (NASDAQ: NBRV) stock plunged by 2.75% at the last close whereas the NBRV stock price rises by 3.77% in the pre-market trading session. Nabriva Therapeutics is a pharmaceutical business focused on the research and marketing of novel anti-infective drugs for the treatment of serious illnesses.

NBRV stock’ Update

Nabriva Therapeutics reported that it has reached a deal with Vizient to make XENLETA, which addresses community-acquired bacterial pneumonia (CABP), available to Vizient’s Pharmacy Network Program as a contracted product. With the purpose to enhance patient care and minimize costs, Vizient offers knowledge, analytics, and advisory services, as well as a contract portfolio totaling more than $110 billion in annual purchasing volume.

25-cent Stock Takes $11T Commodities Sector Digital

One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.

All the details are in the FREE online report you can get here.


Nabriva CEO Ted Schroeder stated that,

They are encouraged by Vizient’s call to make XENLETA accessible to their Hospital Pharmacy Network, which will allow access across Vizient member hospitals, which account for more than half of all hospitals in the United States. According to data from the Healthcare Cost and Utilization Project, roughly 3 million adults are treated with CABP in hospitals each year. Furthermore, many of these individuals may be more susceptible to the side effects of respiratory fluoroquinolones or live in areas where macrolide resistance is common (>25 percent). They’re excited about the prospect of providing clinicians with a short-course, IV and oral monotherapy treatment method for their CABP patients that fulfills these healthcare problems.

Recent Development

In Taiwan, Nabriva Therapeutics’ partner, Sumitomo Pharmaceuticals (Suzhou) Co., has received clearance to sell XENLETA (lefamulin) oral and intravenous (IV) formulations for the cure of community-acquired pneumonia (CAP) in adults.

In May 2021, Nabriva signed a deal with Sumitomo Pharmaceuticals (Suzhou) which is a Chinese unit of Sumitomo Dainippon Pharma, for the development and commercialization of lefamulin in the Greater China Region. However, The exact date of XENLETA’s introduction in Taiwan is unclear.


Please enter your comment!
Please enter your name here